PubRank

RAN Translation in Huntington Disease.

PubWeight™: 1.00‹?› | Rank: Top 15%

🔗 View Article (PMID 26590344)

Published in Neuron on November 18, 2015

Authors

Monica Bañez-Coronel1, Fatma Ayhan1, Alex D Tarabochia1, Tao Zu1, Barbara A Perez1, Solaleh Khoramian Tusi2, Olga Pletnikova3, David R Borchelt4, Christopher A Ross5, Russell L Margolis6, Anthony T Yachnis7, Juan C Troncoso8, Laura P W Ranum9

Author Affiliations

1: Center for NeuroGenetics, University of Florida, Gainesville, FL 32610, USA; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
2: Center for NeuroGenetics, University of Florida, Gainesville, FL 32610, USA; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA; Genetics Institute, University of Florida, Gainesville, FL 32610, USA.
3: Department of Pathology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA.
4: Center for NeuroGenetics, University of Florida, Gainesville, FL 32610, USA; Department of Neuroscience, University of Florida, Gainesville, FL 32610, USA.
5: Division of Neurobiology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Psychiatry, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Pharmacology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neuroscience, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Program in Cellular and Molecular Medicine, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Baltimore Huntington's Disease Center, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA.
6: Division of Neurobiology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Psychiatry, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neuroscience, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Baltimore Huntington's Disease Center, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA.
7: Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
8: Department of Pathology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, The John Hopkins University School of Medicine, Baltimore, MD 21205, USA.
9: Center for NeuroGenetics, University of Florida, Gainesville, FL 32610, USA; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA; Department of Neurology, University of Florida, Gainesville, FL 32610, USA; Genetics Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: ranum@ufl.edu.

Articles citing this ↘

There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res (2016) 0.85

Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest (2016) 0.85

RNA-binding proteins with prion-like domains in health and disease. Biochem J (2017) 0.81

CGG Repeat-Associated Non-AUG Translation Utilizes a Cap-Dependent Scanning Mechanism of Initiation to Produce Toxic Proteins. Mol Cell (2016) 0.81

RAN translation-What makes it run? Brain Res (2016) 0.81

Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cell Mol Neurobiol (2016) 0.78

Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease? PLoS One (2017) 0.77

AAV: An Overview of Unanswered Questions. Hum Gene Ther (2017) 0.77

Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion. Front Mol Neurosci (2016) 0.77

CELL BIOLOGY. Disrupted nuclear import-export in neurodegeneration. Science (2016) 0.77

Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann Neurol (2016) 0.75

Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs. Front Cell Neurosci (2016) 0.75

RNA toxicity and foci formation in microsatellite expansion diseases. Curr Opin Genet Dev (2017) 0.75

Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease. J Huntingtons Dis (2016) 0.75

Post-translational modifications (PTMs), identified on endogenous huntingtin, cluster within proteolytic domains between HEAT repeats. J Proteome Res (2017) 0.75

Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci (2017) 0.75

SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat Commun (2017) 0.75

Alterations in mRNA 3' UTR Isoform Abundance Accompany Gene Expression Changes in Human Huntington's Disease Brains. Cell Rep (2017) 0.75

Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol (2017) 0.75

Articles cited by this ↗

Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45

The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science (2013) 6.34

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet (1999) 4.06

Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A (2010) 3.58

Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54

CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron (2013) 2.94

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78

RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31

Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord (2006) 2.23

Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88

Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull (2010) 1.79

Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res (2005) 1.43

A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum Mol Genet (2011) 1.39

Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol (1991) 1.27

In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology (2004) 1.24

The gait abnormality of Huntington's disease. Neurology (1985) 1.23

A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet (2012) 1.20

Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. Nucleic Acids Res (2012) 1.20

Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12

Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts. Hum Mol Genet (2005) 1.12

Polyglutamine pathogenesis. Philos Trans R Soc Lond B Biol Sci (1999) 1.08

Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr Opin Genet Dev (2014) 1.06

Polyalanine and polyserine frameshift products in Huntington's disease. J Med Genet (2006) 1.06

Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology (1999) 1.05

Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav (2011) 0.98

CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum Mol Genet (2000) 0.97

Early onset Huntington disease: a neuronal degeneration syndrome. Eur J Pediatr (2004) 0.97

Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J Neuropathol Exp Neurol (2009) 0.96

Diagnosis of Huntington disease. Clin Chem (2003) 0.95

Harnessing immune alterations in neurodegenerative diseases. Neuron (2009) 0.95

Expanded ATXN3 frameshifting events are toxic in Drosophila and mammalian neuron models. Hum Mol Genet (2012) 0.94

Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol (2012) 0.92

Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J (2013) 0.90

Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord (2014) 0.90

Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol (2012) 0.86

Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo. J Biol Chem (2015) 0.79

Articles by these authors ⇆

C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron (2016) 1.31

RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2. Neuron (2017) 0.75